Literature DB >> 32714617

Molecular Heterogeneity in Cystic Fibrosis.

Hasret A Civan1, Serhat Seyhan2.   

Abstract

We aimed to evaluate type, frequency, and variety of pathogenic variants according to clinical and demographic features of children diagnosed with cystic fibrosis (CF). Twenty-five CF patients were evaluated retrospectively. Patients' demographics, physical examination, imaging, laboratory, and molecular pathogenic variant analysis findings were evaluated. Phe508del was the most frequently (33.3%) detected pathogenic variant, followed by point pathogenic variants E92K, 1898 + lGA/7T/7T, and 2789 + 5GA, respectively. Statistically higher rates of pathogenic variants were detected in male patients. The most frequently detected pathogenic variant was Phe508del. The identification of nine additional pathogenic variants of Phe508del revealed the heterogeneous nature of the CF. © Thieme Medical Publishers.

Entities:  

Keywords:  Phe508del; cystic fibrosis; cystic fibrosis transmembrane conductance regulator

Year:  2020        PMID: 32714617      PMCID: PMC7375840          DOI: 10.1055/s-0040-1701646

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  20 in total

1.  Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries.

Authors:  Gita Mehta; Milan Macek; Anil Mehta
Journal:  J Cyst Fibros       Date:  2010-11-01       Impact factor: 5.482

2.  Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis.

Authors:  Michael P Boyle; Michelle L Noschese; Sharon L Watts; Marsha E Davis; Shane E Stenner; Noah Lechtzin
Journal:  Am J Respir Crit Care Med       Date:  2005-04-28       Impact factor: 21.405

3.  Unusual segregation of cystic fibrosis allele to males.

Authors:  A Kitzis; J C Chomel; J C Kaplan; G Giraud; A Labbe; B Dastugue; V Dumur; J P Farriaux; P Roussel; R Williamson
Journal:  Nature       Date:  1988-05-19       Impact factor: 49.962

4.  The changing epidemiology and demography of cystic fibrosis.

Authors:  Anne L Stephenson; Sanja Stanojevic; Jenna Sykes; Pierre-Regis Burgel
Journal:  Presse Med       Date:  2017-05-26       Impact factor: 1.228

Review 5.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

Review 6.  Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease.

Authors:  Dominique Debray; Deirdre Kelly; Roderick Houwen; Birgitta Strandvik; Carla Colombo
Journal:  J Cyst Fibros       Date:  2011-06       Impact factor: 5.482

7.  Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis.

Authors:  Catherine Gangell; Samantha Gard; Tonia Douglas; Judy Park; Nicholas de Klerk; Tony Keil; Siobhain Brennan; Sarath Ranganathan; Roy Robins-Browne; Peter D Sly
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

8.  Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation.

Authors:  Alisha J Rovner; Virginia A Stallings; Joan I Schall; Mary B Leonard; Babette S Zemel
Journal:  Am J Clin Nutr       Date:  2007-12       Impact factor: 7.045

Review 9.  New and emerging targeted therapies for cystic fibrosis.

Authors:  Bradley S Quon; Steven M Rowe
Journal:  BMJ       Date:  2016-03-30

10.  ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.

Authors:  Sandra Pankow; Casimir Bamberger; Diego Calzolari; Salvador Martínez-Bartolomé; Mathieu Lavallée-Adam; William E Balch; John R Yates
Journal:  Nature       Date:  2015-11-30       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.